Trodelvy (Sacituzumab Govitecan) in India: A Sourcing Guide for Hospitals Treating Triple-Negative Breast Cancer
Trodelvy has become an increasingly requested medicine among Indian oncology centres treating triple-negative breast cancer, a subtype known for its aggressive course and historically limited treatment options. As demand for this antibody-drug conjugate grows, hospital procurement teams and pharmacies are asking more practical questions — less about the science, which is well established in oncology […]
Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called […]
Enhertu and the ADC Revolution — Why Antibody-Drug Conjugates Are the Most Important Development in Cancer Treatment in 2026
In December 2019 the FDA approved a new cancer medicine that most oncologists had never heard of. By 2024 it had become the best-selling antibody-drug conjugate in the world — generating USD 3.75 billion in annual sales. By early 2026 it had received Priority Review for yet another new indication and was being described by […]